ClinicalTrials.gg
RecruitingNCT05122962PACTUpdated Feb 5, 2026

Pathophysiologic Mechanism for Arrhythmias and Impaired Aerobic Capacity in Tetralogy of Fallot and Other Congenital Heart Diseases

An observational study in Tetralogy of Fallot and Congenital Heart Disease, sponsored by Mayo Clinic. Recruiting at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-02-05.

Sponsored by Mayo Clinic · Observational

How we know

From the registry’s dates

  • Started Nov 2021; still recruiting 5 years later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
300
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 32 studies in Tetralogy of Fallot with a site in United States — 7 open to participants now, 12 under way, none of them phase 3. Tetralogy of Fallot · United States.

Planned enrollment
5th of 12
300 · median 152
Started
2021
with 2 others
Observational
12 of 32
4 open now
Primary completion
2026-10
later than 5 of 11 live
Registered
25th of 32
by date

Among the 32 studies in Tetralogy of Fallot with a site in United States, this one is the 5th largest by planned enrollment of the 12 observational ones that give a count, is one of 3 that started in 2021, is one of 12 observational ones, reaches primary completion later than 5 of the 11 other live ones, and was the 25th registered.

Tetralogy of Fallot

92 studies on the registry are indexed under Tetralogy of Fallot; 25 are open to participants now.

Browse Tetralogy of Fallot studies →

Open to participants now

7 of the 32 studies in Tetralogy of Fallot with a site in United States are open now. Recruiting first, the newest first:

1 more — sign in →

All 7 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 17 Tetralogy of Fallot studies recruiting now, 8 (47%) set no upper age limit and 9 (53%) stop at 75 or younger; 13 take children under 18; 1 takes healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 32 studies in Tetralogy of Fallot with a site in United States, or all of them as a file.
02

Study summary

This study is being done to determine the mechanism(s) contributing to the onset of symptoms (i.e. shortness of breath and/or palpitations) as well as changes in heart structure in patients with congenital heart disease (CHD)

03

Conditions studied

  • Tetralogy of Fallot
  • Congenital Heart Disease
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

This will be a prospective study of patients with congenital heart disease receiving care at Mayo Clinic Rochester, MN.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Moderate (or greater) PR based on quantitative Doppler echocardiography.
  • Repaired TOF
  • Congenital Heart Disease diagnosis including but not limited to Ebstein's anomaly, coarctation of the aorta (COA), Fontan palliation, transposition of the great arteries, congenitally corrected transposition of the great arteries.

Exclusion criteria

Exclusion Criteria:

  • Pregnant Women
  • Unable to undergo CMRI
05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
300 participants (estimated)
Patient registry
No

Interventions

  • Diagnostic testRemote Heart Rhythm Monitoring

    We will be looking to see if remote heart rhythm monitoring for 30 days at baseline, 12, and 24 months, helps for early identification of adverse cardiac events.

06

What researchers measure

Primary outcomes

  1. Right Heart Remodeling

    Right Heart Remodeling measured via right atrial reservoir strain (%).

    Time frame: 24 Months

Secondary outcomes

  1. Incident arrhythmias

    Incident of atrial flutter, atrial fibrillation, atrial tachycardia, and/or ventricular tachycardia.

    Time frame: 24 Months

  2. Aerobic Capacity

    Aerobic Capacity measured as maximal oxygen consumption (ml/kg/min).

    Time frame: 24 Months

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Nov 2021 (actual). Primary completion is estimated for Oct 2026, 59 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 4, 2021
First posted
Nov 17, 2021
StartActual
Nov 1, 2021
Primary completionEst.
Oct 2026
CompletionEst.
Oct 2026
Last update
Feb 5, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 5, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05122962
Lead sponsor
Mayo Clinic
Responsible party
Alexander C. Egbe (Principal Investigator, Mayo Clinic) — Principal investigator
First posted
Nov 17, 2021
Start date
Nov 1, 2021
Primary completion
Oct 2026 (estimated)
Completion
Oct 2026 (estimated)
Last update
Feb 5, 2026

Study contacts

Halley Davison
Contact
RSTACHDRESPRG@mayo.edu
507-422-6246
Alexander Egbe, MBBS, MPH
principal investigator · Mayo Clinic

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion